HomeCompareABT vs GPN

ABT vs GPN: Dividend Comparison 2026

ABT yields 2.36% · GPN yields 1.51%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABT wins by $503.1K in total portfolio value
10 years
ABT
ABT
● Live price
2.36%
Share price
$101.89
Annual div
$2.40
5Y div CAGR
63.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$533.6K
Annual income
$328,772.04
Full ABT calculator →
GPN
GPN
● Live price
1.51%
Share price
$66.30
Annual div
$1.00
5Y div CAGR
27.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$2,458.46
Full GPN calculator →

Portfolio growth — ABT vs GPN

📍 ABT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABTGPN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABT + GPN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABT pays
GPN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABT
Annual income on $10K today (after 15% tax)
$200.23/yr
After 10yr DRIP, annual income (after tax)
$279,456.23/yr
GPN
Annual income on $10K today (after 15% tax)
$128.21/yr
After 10yr DRIP, annual income (after tax)
$2,089.69/yr
At 15% tax rate, ABT beats the other by $277,366.54/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABT + GPN for your $10,000?

ABT: 50%GPN: 50%
100% GPN50/50100% ABT
Portfolio after 10yr
$282.1K
Annual income
$165,615.25/yr
Blended yield
58.72%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GPN right now

ABT
Analyst Ratings
30
Buy
10
Hold
Consensus: Buy
Price Target
$137.67
+35.1% upside vs current
Range: $120.00 — $158.00
Altman Z
4.9
Piotroski
6/9
GPN
Analyst Ratings
37
Buy
21
Hold
4
Sell
Consensus: Buy
Price Target
$94.25
+42.2% upside vs current
Range: $80.00 — $109.00
Altman Z
0.9
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABT buys
0
GPN buys
0
No recent congressional trades found for ABT or GPN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABTGPN
Forward yield2.36%1.51%
Annual dividend / share$2.40$1.00
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR63.2%27.6%
Portfolio after 10y$533.6K$30.5K
Annual income after 10y$328,772.04$2,458.46
Total dividends collected$492.4K$9.1K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuyBuy
Analyst price target$137.67$94.25

Year-by-year: ABT vs GPN ($10,000, DRIP)

YearABT PortfolioABT Income/yrGPN PortfolioGPN Income/yrGap
1← crossover$11,084$384.43$10,892$192.46+$192.00ABT
2$12,510$649.94$11,905$249.99+$605.00ABT
3$14,505$1,118.82$13,064$325.83+$1.4KABT
4$17,499$1,978.53$14,405$426.40+$3.1KABT
5$22,364$3,640.59$15,974$560.68+$6.4KABT
6$31,026$7,096.70$17,834$741.46+$13.2KABT
7$48,215$15,016.56$20,069$987.14+$28.1KABT
8$87,182$35,592.30$22,799$1,324.75+$64.4KABT
9$191,446$98,161.15$26,189$1,794.67+$165.3KABT
10$533,619$328,772.04$30,481$2,458.46+$503.1KABT

ABT vs GPN: Complete Analysis 2026

ABTHealthcare

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Full ABT Calculator →

GPNStock

Global Payments Inc. provides payment technology and software solutions for card, electronic, check, and digital-based payments in the Americas, Europe, and the Asia-Pacific. It operates through three segments: Merchant Solutions, Issuer Solutions, and Business and Consumer Solutions. The Merchant Solutions segment offers authorization services, settlement and funding services, customer support and help-desk functions, chargeback resolution, terminal rental, sales and deployment, payment security services, consolidated billing and statements, and on-line reporting services. This segment also provides an array of enterprise software solutions that streamline business operations of its customers in various vertical markets; and value-added services, such as point-of-sale solutions, and analytic and engagement tools, as well as payroll and human capital management services. The Issuer Solutions segment offers solutions that enable financial institutions and retailers to manage their card portfolios through a platform; and commercial payments and ePayables solutions for businesses and governments. The Business and Consumer Solutions segment provides general-purpose reloadable prepaid debit and payroll cards, demand deposit accounts, and other financial service solutions to the underbanked and other consumers, and businesses under the Netspend brand. It markets its products and services through direct sales force, trade associations, agent and enterprise software providers, referral arrangements with value-added resellers, and independent sales organizations. The company was founded in 1967 and is headquartered in Atlanta, Georgia.

Full GPN Calculator →
📬

Get this ABT vs GPN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABT vs SCHDABT vs JEPIABT vs OABT vs KOABT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.